• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biohaven Ltd (NY: BHVN )

    35.86 +1.15 (+3.31%)
    Streaming Delayed Price Updated: 12:32 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Biohaven Ltd

    < Previous 1 2 3 4 5 6 7 8 Next >
    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
    Investors are constantly on the hunt for undervalued, under-followed, and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    What's Going On Pfizer's Subsidiary Biohaven Stock?
    Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
    Via Benzinga
    Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers 
    Via Benzinga
    NYSE:BHVN Investor Alert: Investigation Concerning Possible Securities Laws Violations by Biohaven Ltd.
    San Diego, CA -- (SBWIRE) -- 08/23/2023 -- Biohaven Ltd. is under investigation over potential securities laws violations in connection with certain financial statements. 
    Via SBWire
    Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
    The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
    Via Investor's Business Daily
    Why Biohaven Stock Is Skyrocketing Today
    Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain. 
    Via The Motley Fool
    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    US Stocks Open Higher; Costco Posts Upbeat Earnings
    U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.14% to 33,664.90 while the NASDAQ... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biohaven Stock Is Plunging Today - Here's Why
    Biohaven Ltd (NASDAQ: BHVN) shares are down after the company announced multiple  
    Via Benzinga
    Why Biohaven Stock Is Crashing Today
    The clinical-stage biotech is going to remain in the clinical stage longer than it hoped. 
    Via The Motley Fool
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Cramer Warns Investors About This AI Company Up 146% YTD: 'Too Much Hype, Too Much Fluff'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Micron Technology, Inc. (NASDAQ: MU) is "coming out of the trough, I agree with the hype. 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    $2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
    Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Biohaven Stock Caught Fire This Week
    Investors are excited about the company's recent progress. 
    Via The Motley Fool
    Recap: Biohaven Q1 Earnings
    Via Benzinga
    Will The Dow Make History Today With A 14 Straight?
    The blue-chip index is slightly above breakeven at midday, while the S&P 500 Index and Nasdaq Composite are higher after another batch of earnings. 
    Via Talk Markets
    Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    2 Growth Stocks With Major Incoming Catalysts
    Binary events slated for July could quickly send these biotech stocks through the roof. 
    Via The Motley Fool
    Top 5 Health Care Stocks That May Crash This Month
    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
    Via Benzinga
    Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
    The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
    Via Benzinga
    How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
    Shares surged into and out of the company's R&D Day, which included a surprise. 
    Via Investor's Business Daily
    Tower Semiconductor, XP And 3 Stocks To Watch Heading Into Monday
    With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
    Via Benzinga
    Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns
    The first quarter of 2023 was positive for the U.S. stock market as a whole, with the S&P 500 index faithfully tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), rising by 6%. 
    Via Benzinga
    Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
    HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
    Via Talk Markets
    Analysts Holding As Pfizer Waits On Two Phase 3 Studies
    Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
    Via MarketBeat
    Topics Bankruptcy
    Exposures Financial Legal
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.